Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 354

1.

Structural and Functional Remodeling of Amygdala GABAergic Synapses in Associative Fear Learning.

Kasugai Y, Vogel E, Hörtnagl H, Schönherr S, Paradiso E, Hauschild M, Göbel G, Milenkovic I, Peterschmitt Y, Tasan R, Sperk G, Shigemoto R, Sieghart W, Singewald N, Lüthi A, Ferraguti F.

Neuron. 2019 Aug 27. pii: S0896-6273(19)30697-X. doi: 10.1016/j.neuron.2019.08.013. [Epub ahead of print]

PMID:
31543297
2.

Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma.

Scheiner B, Ulbrich G, Mandorfer M, Reiberger T, Müller C, Waneck F, Trauner M, Kölblinger C, Ferlitsch A, Sieghart W, Peck-Radosavljevic M, Pinter M.

United European Gastroenterol J. 2019 Jul;7(6):850-858. doi: 10.1177/2050640619840199. Epub 2019 Mar 21.

3.

Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma.

Scheiner B, Kirstein M, Popp S, Hucke F, Bota S, Rohr-Udilova N, Reiberger T, Müller C, Trauner M, Peck-Radosavljevic M, Vogel A, Sieghart W, Pinter M.

Liver Cancer. 2019 May;8(3):203-217. doi: 10.1159/000489833. Epub 2018 Jun 22.

4.

C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation.

Meischl T, Rasoul-Rockenschaub S, Györi G, Sieghart W, Reiberger T, Trauner M, Soliman T, Berlakovich G, Pinter M.

PLoS One. 2019 May 29;14(5):e0216677. doi: 10.1371/journal.pone.0216677. eCollection 2019.

5.

Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.

Scheiner B, Kirstein MM, Hucke F, Finkelmeier F, Schulze K, von Felden J, Koch S, Schwabl P, Hinrichs JB, Waneck F, Waidmann O, Reiberger T, Müller C, Sieghart W, Trauner M, Weinmann A, Wege H, Trojan J, Peck-Radosavljevic M, Vogel A, Pinter M.

Aliment Pharmacol Ther. 2019 May;49(10):1323-1333. doi: 10.1111/apt.15245. Epub 2019 Apr 12.

6.

Trigeminal neuropathic pain development and maintenance in rats are suppressed by a positive modulator of α6 GABAA receptors.

Vasović D, Divović B, Treven M, Knutson DE, Steudle F, Scholze P, Obradović A, Fabjan J, Brković B, Sieghart W, Ernst M, Cook JM, Savić MM.

Eur J Pain. 2019 May;23(5):973-984. doi: 10.1002/ejp.1365. Epub 2019 Feb 4.

PMID:
30633839
7.
8.

Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis.

Bucsics T, Grasl B, Ferlitsch A, Schwabl P, Mandorfer M, Zinober K, Stern R, Chromy D, Scheiner B, Sieghart W, Peck-Radosavljevic M, Trauner M, Reiberger T.

Ultrasound Med Biol. 2018 Dec;44(12):2578-2586. doi: 10.1016/j.ultrasmedbio.2018.07.031. Epub 2018 Sep 18.

PMID:
30241728
9.

Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure?

Pinter M, Sieghart W.

Memo. 2018;11(3):185-192. doi: 10.1007/s12254-018-0431-z. Epub 2018 Aug 24. Review.

10.

The α6 subunit-containing GABAA receptor: A novel drug target for inhibition of trigeminal activation.

Fan PC, Lai TH, Hor CC, Lee MT, Huang P, Sieghart W, Ernst M, Knutson DE, Cook J, Chiou LC.

Neuropharmacology. 2018 Sep 15;140:1-13. doi: 10.1016/j.neuropharm.2018.07.017. Epub 2018 Jul 21.

11.

Transforming Growth Factor-β and Axl Induce CXCL5 and Neutrophil Recruitment in Hepatocellular Carcinoma.

Haider C, Hnat J, Wagner R, Huber H, Timelthaler G, Grubinger M, Coulouarn C, Schreiner W, Schlangen K, Sieghart W, Peck-Radosavljevic M, Mikulits W.

Hepatology. 2019 Jan;69(1):222-236. doi: 10.1002/hep.30166. Epub 2018 Dec 20.

12.

Engineered Flumazenil Recognition Site Provides Mechanistic Insight Governing Benzodiazepine Modulation in GABAA Receptors.

Siebert DCB, Bampali K, Puthenkalam R, Varagic Z, Sarto-Jackson I, Scholze P, Sieghart W, Mihovilovic MD, Schnürch M, Ernst M.

ACS Chem Biol. 2018 Aug 17;13(8):2040-2047. doi: 10.1021/acschembio.8b00145. Epub 2018 Jul 23.

PMID:
29989390
13.

Evidence That Sedative Effects of Benzodiazepines Involve Unexpected GABAA Receptor Subtypes: Quantitative Observation Studies in Rhesus Monkeys.

Duke AN, Meng Z, Platt DM, Atack JR, Dawson GR, Reynolds DS, Tiruveedhula VVNPB, Li G, Stephen MR, Sieghart W, Cook JM, Rowlett JK.

J Pharmacol Exp Ther. 2018 Jul;366(1):145-157. doi: 10.1124/jpet.118.249250. Epub 2018 May 2.

14.

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, Rota Caremoli E, Porta C, Daniele B, Bolondi L, Mazzaferro V, Harris W, Damjanov N, Pastorelli D, Reig M, Knox J, Negri F, Trojan J, López López C, Personeni N, Decaens T, Dupuy M, Sieghart W, Abbadessa G, Schwartz B, Lamar M, Goldberg T, Shuster D, Santoro A, Bruix J.

Lancet Oncol. 2018 May;19(5):682-693. doi: 10.1016/S1470-2045(18)30146-3. Epub 2018 Apr 3.

PMID:
29625879
15.

Cerebellar α6 -subunit-containing GABAA receptors: a novel therapeutic target for disrupted prepulse inhibition in neuropsychiatric disorders.

Chiou LC, Lee HJ, Ernst M, Huang WJ, Chou JF, Chen HL, Mouri A, Chen LC, Treven M, Mamiya T, Fan PC, Knutson DE, Witzigmann C, Cook J, Sieghart W, Nabeshima T.

Br J Pharmacol. 2018 Jun;175(12):2414-2427. doi: 10.1111/bph.14198. Epub 2018 May 10.

16.

Design and Synthesis of Novel Deuterated Ligands Functionally Selective for the γ-Aminobutyric Acid Type A Receptor (GABAAR) α6 Subtype with Improved Metabolic Stability and Enhanced Bioavailability.

Knutson DE, Kodali R, Divović B, Treven M, Stephen MR, Zahn NM, Dobričić V, Huber AT, Meirelles MA, Verma RS, Wimmer L, Witzigmann C, Arnold LA, Chiou LC, Ernst M, Mihovilovic MD, Savić MM, Sieghart W, Cook JM.

J Med Chem. 2018 Mar 22;61(6):2422-2446. doi: 10.1021/acs.jmedchem.7b01664. Epub 2018 Mar 6.

PMID:
29481759
17.

Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding - A two decades experience.

Bucsics T, Schoder M, Diermayr M, Feldner-Busztin M, Goeschl N, Bauer D, Schwabl P, Mandorfer M, Angermayr B, Cejna M, Ferlitsch A, Sieghart W, Trauner M, Peck-Radosavljevic M, Karner J, Karnel F, Reiberger T.

PLoS One. 2018 Jan 9;13(1):e0189414. doi: 10.1371/journal.pone.0189414. eCollection 2018.

18.

Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma.

Pinter M, Weinmann A, Wörns MA, Hucke F, Bota S, Marquardt JU, Duda DG, Jain RK, Galle PR, Trauner M, Peck-Radosavljevic M, Sieghart W.

United European Gastroenterol J. 2017 Nov;5(7):987-996. doi: 10.1177/2050640617695698. Epub 2017 Feb 26.

19.

GABAA receptor subunits in the human amygdala and hippocampus: Immunohistochemical distribution of 7 subunits.

Stefanits H, Milenkovic I, Mahr N, Pataraia E, Hainfellner JA, Kovacs GG, Sieghart W, Yilmazer-Hanke D, Czech T.

J Comp Neurol. 2018 Feb 1;526(2):324-348. doi: 10.1002/cne.24337. Epub 2017 Oct 29.

PMID:
29023704
20.

Oxidative stress mediates an increased formation of vascular endothelial growth factor in human hepatocarcinoma cells exposed to erlotinib.

Rohr-Udilova N, Klinglmüller F, Seif M, Hayden H, Bilban M, Pinter M, Stolze K, Sieghart W, Peck-Radosavljevic M, Trauner M.

Oncotarget. 2017 Jul 6;8(34):57109-57120. doi: 10.18632/oncotarget.19055. eCollection 2017 Aug 22.

21.

Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice.

Bucsics T, Schoder M, Goeschl N, Schwabl P, Mandorfer M, Diermayr M, Feldner M, Riedl F, Bauer D, Angermayr B, Cejna M, Ferlitsch A, Sieghart W, Trauner M, Peck-Radosavljevic M, Karner J, Karnel F, Reiberger T.

Dig Liver Dis. 2017 Dec;49(12):1360-1367. doi: 10.1016/j.dld.2017.08.002. Epub 2017 Aug 8.

PMID:
28869158
22.

The impact of thyroid hormones on patients with hepatocellular carcinoma.

Pinter M, Haupt L, Hucke F, Bota S, Bucsics T, Trauner M, Peck-Radosavljevic M, Sieghart W.

PLoS One. 2017 Aug 3;12(8):e0181878. doi: 10.1371/journal.pone.0181878. eCollection 2017.

23.

Gliotoxin Targets Nuclear NOTCH2 in Human Solid Tumor Derived Cell Lines In Vitro and Inhibits Melanoma Growth in Xenograft Mouse Model.

Hubmann R, Sieghart W, Schnabl S, Araghi M, Hilgarth M, Reiter M, Demirtas D, Valent P, Zielinski C, Jäger U, Shehata M.

Front Pharmacol. 2017 Jul 7;8:319. doi: 10.3389/fphar.2017.00319. eCollection 2017.

24.

Early response evaluation using CT-perfusion one day after transarterial chemoembolization for HCC predicts treatment response and long-term disease control.

Tamandl D, Waneck F, Sieghart W, Unterhumer S, Kölblinger C, Baltzer P, Ba-Ssalamah A, Loewe C.

Eur J Radiol. 2017 May;90:73-80. doi: 10.1016/j.ejrad.2017.02.032. Epub 2017 Feb 22.

PMID:
28583650
25.

Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices.

Scheiner B, Parada-Rodriguez D, Bucsics T, Schwabl P, Mandorfer M, Pfisterer N, Riedl F, Sieghart W, Ferlitsch A, Trauner M, Peck-Radosavljevic M, Reiberger T.

Scand J Gastroenterol. 2017 Sep;52(9):1008-1015. doi: 10.1080/00365521.2017.1329456. Epub 2017 May 22.

PMID:
28532189
26.

Cancer and liver cirrhosis: implications on prognosis and management.

Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W.

ESMO Open. 2016 Mar 17;1(2):e000042. eCollection 2016. Review.

27.

Personalized treatment of patients with very early hepatocellular carcinoma.

Vitale A, Peck-Radosavljevic M, Giannini EG, Vibert E, Sieghart W, Van Poucke S, Pawlik TM.

J Hepatol. 2017 Feb;66(2):412-423. doi: 10.1016/j.jhep.2016.09.012. Epub 2016 Sep 24. Review.

PMID:
27677712
28.

First In Vivo Testing of Compounds Targeting Group 3 Medulloblastomas Using an Implantable Microdevice as a New Paradigm for Drug Development.

Jonas O, Calligaris D, Methuku KR, Poe MM, Francois JP, Tranghese F, Changelian A, Sieghart W, Ernst M, Krummel DA, Cook JM, Pomeroy SL, Cima M, Agar NY, Langer R, Sengupta S.

J Biomed Nanotechnol. 2016 Jun;12(6):1297-302.

29.

Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension.

Mandorfer M, Kozbial K, Schwabl P, Freissmuth C, Schwarzer R, Stern R, Chromy D, Stättermayer AF, Reiberger T, Beinhardt S, Sieghart W, Trauner M, Hofer H, Ferlitsch A, Ferenci P, Peck-Radosavljevic M.

J Hepatol. 2016 Oct;65(4):692-699. doi: 10.1016/j.jhep.2016.05.027. Epub 2016 May 27.

PMID:
27242316
30.

The trigger matters - outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites.

Bucsics T, Schwabl P, Mandorfer M, Bota S, Sieghart W, Ferlitsch A, Trauner M, Reiberger T, Peck-Radosavljevic M.

Liver Int. 2016 Nov;36(11):1649-1656. doi: 10.1111/liv.13160. Epub 2016 Jun 30.

PMID:
27169985
31.

Formation of GABAA receptor complexes containing α1 and α5 subunits is paralleling a multiple T-maze learning task in mice.

Ghafari M, Falsafi SK, Szodorai E, Kim EJ, Li L, Höger H, Berger J, Fuchs K, Sieghart W, Lubec G.

Brain Struct Funct. 2017 Jan;222(1):549-561. doi: 10.1007/s00429-016-1233-x. Epub 2016 May 7.

PMID:
27155990
32.

Mutagenesis and computational docking studies support the existence of a histamine binding site at the extracellular β3+β3- interface of homooligomeric β3 GABAA receptors.

Hoerbelt P, Ramerstorfer J, Ernst M, Sieghart W, Thomson JL, Hough LB, Fleck MW.

Neuropharmacology. 2016 Sep;108:252-63. doi: 10.1016/j.neuropharm.2016.04.042. Epub 2016 Apr 30.

PMID:
27140694
33.

Early postnatal switch in GABAA receptor α-subunits in the reticular thalamic nucleus.

Pangratz-Fuehrer S, Sieghart W, Rudolph U, Parada I, Huguenard JR.

J Neurophysiol. 2016 Mar;115(3):1183-95. doi: 10.1152/jn.00905.2015. Epub 2015 Dec 2.

34.

Neuropilin-2 induced by transforming growth factor-β augments migration of hepatocellular carcinoma cells.

Wittmann P, Grubinger M, Gröger C, Huber H, Sieghart W, Peck-Radosavljevic M, Mikulits W.

BMC Cancer. 2015 Nov 16;15:909. doi: 10.1186/s12885-015-1919-0.

35.

The α1, α2, α3, and γ2 subunits of GABAA receptors show characteristic spatial and temporal expression patterns in rhombencephalic structures during normal human brain development.

Stojanovic T, Capo I, Aronica E, Adle-Biassette H, Höger H, Sieghart W, Kovacs GG, Milenkovic I.

J Comp Neurol. 2016 Jun 15;524(9):1805-24. doi: 10.1002/cne.23923. Epub 2015 Nov 23.

PMID:
26518133
36.

Neurotoxins from snake venoms and α-conotoxin ImI inhibit functionally active ionotropic γ-aminobutyric acid (GABA) receptors.

Kudryavtsev DS, Shelukhina IV, Son LV, Ojomoko LO, Kryukova EV, Lyukmanova EN, Zhmak MN, Dolgikh DA, Ivanov IA, Kasheverov IE, Starkov VG, Ramerstorfer J, Sieghart W, Tsetlin VI, Utkin YN.

J Biol Chem. 2015 Sep 11;290(37):22747-58. doi: 10.1074/jbc.M115.648824. Epub 2015 Jul 28.

37.

Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo.

Pinter M, Ulbrich G, Sieghart W, Kölblinger C, Reiberger T, Li S, Ferlitsch A, Müller C, Lammer J, Peck-Radosavljevic M.

Radiology. 2015 Dec;277(3):903-12. doi: 10.1148/radiol.2015142140. Epub 2015 Jul 1.

PMID:
26131911
38.

Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: A retrospective cohort study.

Bucsics T, Mandorfer M, Schwabl P, Bota S, Sieghart W, Ferlitsch A, Trauner M, Peck-Radosavljevic M, Reiberger T.

J Gastroenterol Hepatol. 2015 Nov;30(11):1657-65. doi: 10.1111/jgh.13002.

PMID:
25967931
39.

Transarterial chemoembolization: modalities, indication, and patient selection.

Sieghart W, Hucke F, Peck-Radosavljevic M.

J Hepatol. 2015 May;62(5):1187-95. doi: 10.1016/j.jhep.2015.02.010. Epub 2015 Feb 12. Review.

40.

Allosteric modulation of GABAA receptors via multiple drug-binding sites.

Sieghart W.

Adv Pharmacol. 2015;72:53-96. doi: 10.1016/bs.apha.2014.10.002. Epub 2014 Dec 4. Review.

PMID:
25600367
41.

Evaluation of a new balloon occlusion catheter specifically designed for measurement of hepatic venous pressure gradient.

Ferlitsch A, Bota S, Paternostro R, Reiberger T, Mandorfer M, Heinisch B, Salzl P, Schwarzer R, Sieghart W, Peck-Radosavljevic M, Ferlitsch M.

Liver Int. 2015 Sep;35(9):2115-20. doi: 10.1111/liv.12783. Epub 2015 Jan 30.

PMID:
25585656
42.

GABA(A) receptor subtype-selectivity of novel bicuculline derivatives.

Ramerstorfer J, Foppa V, Thiery H, Hermange P, Janody S, Berger ML, Dodd RH, Sieghart W.

Curr Med Chem. 2015;22(6):771-80.

PMID:
25386826
43.

Epidemiological trends of hepatocellular carcinoma in Austria.

Pinter M, Hucke F, Zielonke N, Trauner M, Sieghart W, Peck-Radosavljevic M.

Dig Dis. 2014;32(6):664-9. doi: 10.1159/000367983. Epub 2014 Oct 29.

PMID:
25376282
44.

Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites.

Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Summereder C, Hagmann M, Blacky A, Ferlitsch A, Sieghart W, Trauner M, Peck-Radosavljevic M, Reiberger T.

PLoS One. 2014 Nov 4;9(11):e110503. doi: 10.1371/journal.pone.0110503. eCollection 2014.

45.

Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma.

Reichl P, Dengler M, van Zijl F, Huber H, Führlinger G, Reichel C, Sieghart W, Peck-Radosavljevic M, Grubinger M, Mikulits W.

Hepatology. 2015 Mar;61(3):930-41. doi: 10.1002/hep.27492. Epub 2015 Jan 28.

46.

EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation.

Lanaya H, Natarajan A, Komposch K, Li L, Amberg N, Chen L, Wculek SK, Hammer M, Zenz R, Peck-Radosavljevic M, Sieghart W, Trauner M, Wang H, Sibilia M.

Nat Cell Biol. 2014 Oct;16(10):972-7. doi: 10.1038/ncb3031. Epub 2014 Aug 31.

47.

How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma.

Hucke F, Pinter M, Graziadei I, Bota S, Vogel W, Müller C, Heinzl H, Waneck F, Trauner M, Peck-Radosavljevic M, Sieghart W.

J Hepatol. 2014 Dec;61(6):1287-96. doi: 10.1016/j.jhep.2014.07.002. Epub 2014 Jul 10.

PMID:
25016222
48.

Hedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGF-A expression in hepatocellular carcinoma.

Pinter M, Sieghart W, Schmid M, Dauser B, Prager G, Dienes HP, Trauner M, Peck-Radosavljevic M.

United European Gastroenterol J. 2013 Aug;1(4):265-75. doi: 10.1177/2050640613496605.

49.

Reply to the letters to the editor regarding the sequential ART-score.

Hucke F, Sieghart W, Peck-Radosavljevic M.

J Hepatol. 2014 Jul;61(1):177-8. doi: 10.1016/j.jhep.2014.03.015. Epub 2014 Mar 18. No abstract available.

50.

Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis.

Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M, Hagmann M, Blacky A, Ferlitsch A, Sieghart W, Trauner M, Peck-Radosavljevic M, Reiberger T.

Gastroenterology. 2014 Jun;146(7):1680-90.e1. doi: 10.1053/j.gastro.2014.03.005. Epub 2014 Mar 12.

PMID:
24631577

Supplemental Content

Loading ...
Support Center